Serotonin
|
Basic information |
| Metabolite name | Serotonin |
 | HMDB0000259 |
 |
C00780 |
 |
5202 |
| Synonyms | 5-HT; |
| No. of studies | 115 |
|
Basic information |
| Metabolite name | Serotonin |
| HMDB0000259 |
|
C00780 |
|
5202 |
| Synonyms | 5-HT; |
| No. of studies | 115 |
|
Relationship between Serotonin and depression (count: 115) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M011 | Type4 | sertraline-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M023 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M023 | Type2 | CUMS + high dose of venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M023 | Type2 | CUMS + middle dose of venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M037 | Type2 | sertraline treatment group one-week vs. baseline | Serum | Human | Down |
| Study M037 | Type2 | sertraline treatment group four-week vs. baseline | Serum | Human | Down |
| Study M037 | Type2 | placebo treatment group one-week vs. baseline | Serum | Human | Down |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M079 | Type1 | prolonged LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M079 | Type1 | acute LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M080 | Type2 | SSRI-treated 4-week and 8-week vs. baseline | Plasma | Human | Down |
| Study M080 | Type4 | both response and remission for SSRI-treated 4-week and 8-week vs. baseline | Plasma | Human | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Down |
| Study M1000 | Type1 | ovariectomy group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M1000 | Type2 | ovariectomy + estradiol group vs. ovariectomy group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M1004 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1004 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Down |
| Study M1004 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1004 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1004 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1012 | Type1 | loperamide group vs. control group | Colon | C57BL/6J mouse | Down |
| Study M1012 | Type1 | loperamide group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1012 | Type2 | loperamide + probiotic group vs. loperamide group | Serum | C57BL/6J mouse | Up |
| Study M1012 | Type2 | loperamide + probiotic group vs. loperamide group | Colon | C57BL/6J mouse | Up |
| Study M1013 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M1015 | Type1 | lipopolysaccharide group vs. control group | Cortex | C57BL/6J mouse | Down |
| Study M1015 | Type1 | lipopolysaccharide group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + amitriptyline group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + high dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + middle dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + high dose of soy isoflavones group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + amitriptyline group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + low dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + middle dose of soy isoflavones group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + low dose of soy isoflavones group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Up |
| Study M1031 | Type2 | depression group, after 6-month treatment vs. baseline | Plasma | Human | Down |
| Study M1031 | Type2 | depression group, after 3-month treatment vs. baseline | Plasma | Human | Down |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1046 | Type3 | intraperitoneal ketamine group vs. intraperitoneal control group | Medial prefrontal cortex | BALB/cJ mouse | Up |
| Study M1059 | Type1 | CRS group vs. control group | Serum | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Cortex | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Cecum | Wistar rat | Up |
| Study M1081 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1081 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Serum | C57BL/6 J mouse | Up |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Colon | C57BL/6 J mouse | Up |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1082 | Type1 | interferon gamma group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1082 | Type1 | interferon gamma group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M1082 | Type1 | interferon gamma group vs. control group | Brain | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Serum | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Brain | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Colon | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Brain | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Colon | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Serum | C57BL/6 J mouse | Up |
| Study M1083 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1083 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M1083 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Down |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Brain | C57BL/6 J mouse | Up |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Colon | C57BL/6 J mouse | Up |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Serum | C57BL/6 J mouse | Up |
| Study M1084 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1084 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M1084 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Down |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Brain | C57BL/6 J mouse | Up |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Serum | C57BL/6 J mouse | Up |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Colon | C57BL/6 J mouse | Up |
| Study M1087 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1095 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Down |
| Study M1095 | Type2 | CUMS + matrine group vs. CUMS group | Faece | ICR mouse | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1106 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1106 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1106 | Type2 | CUMS + middle dose of Compound Gaoziban tablet group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1106 | Type2 | CUMS + high dose of Compound Gaoziban tablet group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1107 | Type1 | CRS group vs. control group | Serum | C57/6 J mouse | Down |
| Study M1107 | Type1 | CRS group vs. control group | Colon | C57/6 J mouse | Down |
| Study M1107 | Type1 | CRS + FMT of adolescent depression group vs. CRS + FMT of healthy controls group | Colon | C57/6 J mouse | Down |
| Study M1107 | Type1 | CRS + FMT of adolescent depression group vs. CRS + FMT of healthy controls group | Prefrontal cortex | C57/6 J mouse | Down |
| Study M1107 | Type1 | CRS group vs. control group | Prefrontal cortex | C57/6 J mouse | Down |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Colon | C57/6 J mouse | Up |
| Study M1108 | Type1 | CRS group vs. control group | Serum | C57/6 J mouse | Down |
| Study M1108 | Type1 | CRS group vs. control group | Colon | C57/6 J mouse | Down |
| Study M1108 | Type1 | CRS group vs. control group | Prefrontal cortex | C57/6 J mouse | Down |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Serum | C57/6 J mouse | Up |
| Study M1108 | Type3 | Roseburia Intestinalis. group vs. CRS group | Colon | C57/6 J mouse | Down |
| Study M1118 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M1118 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1118 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1118 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | C57BL/6 mouse | Up |
| Study M1121 | Type3 | TAT-SERT-15C group vs. control group | Dorsal raphe nucleus | C57BL/6J mouse | Down |
| Study M1122 | Type1 | CMS group vs. control group | Dorsal raphe nucleus | C57BL/6J mouse | Up |
| Study M1122 | Type2 | CMS + TAT-SERT-15C group vs. CMS group | Dorsal raphe nucleus | C57BL/6J mouse | Down |
| Study M1122 | Type2 | CMS + fluoxetine group vs. CMS group | Dorsal raphe nucleus | C57BL/6J mouse | Up |
| Study M1123 | Type3 | TAT-SERT-15C group vs. control group | Medial prefrontal cortex | C57BL/6J mouse | Up |
| Study M1123 | Type3 | TAT-SERT-15C group vs. control group | Dorsal raphe nucleus | C57BL/6J mouse | Down |
| Study M1123 | Type3 | TAT-SERT-15C group vs. control group | Ventral hippocampus | C57BL/6J mouse | Up |
| Study M1124 | Type1 | CMS group vs. control group | Ventral hippocampus | C57BL/6J mouse | Down |
| Study M1124 | Type1 | CMS group vs. control group | Medial prefrontal cortex | C57BL/6J mouse | Down |
| Study M1124 | Type2 | CMS + TAT-SERT-15C group vs. CMS group | Medial prefrontal cortex | C57BL/6J mouse | Up |
| Study M1124 | Type2 | CMS + TAT-SERT-15C group vs. CMS group | Ventral hippocampus | C57BL/6J mouse | Up |
| Study M1126 | Type1 | ovariectomy group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1126 | Type2 | ovariectomy + middle dose of Danggui-Shaoyao-San group vs. ovariectomy group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1126 | Type2 | ovariectomy + low dose of Danggui-Shaoyao-San group vs. ovariectomy group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1134 | Type1 | prenatal stress group vs. control group, female offspring | Hippocampus | Swiss mouse | Down |
| Study M1136 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1136 | Type2 | CUMS + low dose of punicalagin group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1136 | Type2 | CUMS + high dose of punicalagin group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1136 | Type2 | CUMS + middle dose of punicalagin group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1141 | Type1 | austere environment group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1142 | Type2 | MDD group, after intermittent theta burst stimulation vs. baseline | Plasma | Human | Down |
| Study M126 | Type1 | LPS group vs. control group | Brain | CD-1 mouse | Up |
| Study M141 | Type1 | LPS group vs. control group | Prefrontal cortex | ICR mouse | Down |
| Study M141 | Type2 | LPS + low dose of JTW group vs. LPS group | Prefrontal cortex | ICR mouse | Up |
| Study M141 | Type2 | LPS +high dose of JTW group vs. LPS group | Prefrontal cortex | ICR mouse | Up |
| Study M141 | Type2 | LPS + fluoxetine group vs. LPS group | Prefrontal cortex | ICR mouse | Up |
| Study M144 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M144 | Type2 | CUMS + high dose of GSTT group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M144 | Type2 | CUMS + middle dose of GSTT group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M144 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M144 | Type2 | CUMS + low dose of GSTT group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M157 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M168 | Type1 | OBX group vs. control group | Cerebrospinal fluid | Wistar rat | Down |
| Study M170 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M170 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M171 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M171 | Type2 | CUMS + DXS group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M171 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M176 | Type1 | CUMS group vs. control group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + low dose of HCPE group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + paroxetine group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + middle dose of HCPE group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M179 | Type1 | CUMS group vs. control group | Hippocampus | BALB/c mouse | Down |
| Study M179 | Type1 | CUMS group vs. control group | Cerebral cortex | BALB/c mouse | Down |
| Study M179 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M179 | Type2 | CUMS + high dose of DNL group vs. CUMS group | Cerebral cortex | BALB/c mouse | Up |
| Study M179 | Type2 | CUMS + middle dose of DNL group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M179 | Type2 | CUMS + high dose of DNL group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M191 | Type1 | CRS group vs. control group | Prefrontal cortex | C57BL/J mouse | Down |
| Study M191 | Type2 | CRS + L-theanine group vs. CRS group | Prefrontal cortex | C57BL/J mouse | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M523 | Type1 | CUMS group vs. control group | Brain | Wistar rat | Down |
| Study M531 | Type2 | MDD with escitalopram/citalopram treatment, 8-week vs. baseline | Plasma | Human | Down |
| Study M533 | Type1 | surgery group vs. control group | Hippocampus | Wistar rat | Down |
| Study M533 | Type2 | surgery + fluoxetine group vs. surgery + vehicle group | Hippocampus | Wistar rat | Up |
| Study M542 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M542 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M558 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M558 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + low dose of volatile oils group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + high dose of volatile oils group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + high dose of terpenoids group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M559 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + high dose of volatile oils group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + high dose of terpenoids group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + low dose of polysaccharides group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M563 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M563 | Type2 | CUMS + TCM group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M570 | Type1 | CMS group vs. control group | Hippocampus | BALB/c mouse | Up |
| Study M570 | Type1 | CMS group vs. control group | Serum | BALB/c mouse | Down |
| Study M574 | Type1 | CMS + n-3 PUFA deficiency group vs. control + n-3 PUFA deficiency group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M581 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M627 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M627 | Type1 | CUMS group vs. control group | Cortex | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + high dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M634 | Type1 | CUMS group vs. control group | Cerebrospinal fluid | C57BL/6 mouse | Down |
| Study M634 | Type2 | CUMS + escitalopram group vs. CUMS group | Cerebrospinal fluid | C57BL/6 mouse | Up |
| Study M634 | Type2 | CUMS + PUFA group vs. CUMS group | Cerebrospinal fluid | C57BL/6 mouse | Up |
| Study M657 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M657 | Type2 | desvenlafaxine-treated MDD group, after vs. before treatment | Plasma | Human | Down |
| Study M657 | Type2 | escitalopram-treated MDD group, after vs. before treatment | Plasma | Human | Down |
| Study M657 | Type4 | escitalopram-treated MDD group, responder vs. non-responder | Plasma | Human | Up |
| Study M665 | Type1 | CRS group vs. control group | Hypothalamus | C57BL/6 mouse | Down |
| Study M684 | Type1 | LPS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M684 | Type2 | LPS + electroacupuncture group vs. LPS group | Hippocampus | Wistar rat | Up |
| Study M692 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M698 | Type2 | CUMS + Saikosaponin A group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M699 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M701 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M710 | Type1 | olfactory bulbectomized group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M710 | Type2 | olfactory bulbectomized + low dose of Rhodioloside group vs. olfactory bulbectomized group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M710 | Type2 | olfactory bulbectomized + high dose of Rhodioloside group vs. olfactory bulbectomized group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M710 | Type2 | olfactory bulbectomized + amitriptyline group vs. olfactory bulbectomized group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M711 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M713 | Type1 | CUMS group vs. control group, week 5 | Hippocampus | C57BL/6 mouse | Down |
| Study M714 | Type1 | corticosterone group vs. control group, week 5 | Hippocampus | C57BL/6 mouse | Down |
| Study M714 | Type1 | corticosterone group vs. control group, week 3 | Hippocampus | C57BL/6 mouse | Down |
| Study M721 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M721 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | C57BL/6J mouse | Up |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Gut | C57BL/6J mouse | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Hippocampus | C57BL/6J mouse | Down |
| Study M722 | Type2 | CUMS-transferred group + 5-hydroxytryptophan group vs. CUMS-transferred group | Serum | C57BL/6J mouse | Up |
| Study M722 | Type2 | CUMS-transferred group + 5-hydroxytryptophan group vs. CUMS-transferred group | Hippocampus | C57BL/6J mouse | Up |
| Study M728 | Type1 | CRS group vs. control group | Prefrontal cortex | C57BL/6 J mouse | Down |
| Study M728 | Type1 | CRS group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M728 | Type2 | CRS + citalopram group vs. CRS group | Prefrontal cortex | C57BL/6 J mouse | Up |
| Study M732 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M736 | Type1 | cuff group vs. control group | Brainstem | C57BL6J mouse | Up |
| Study M741 | Type2 | MDD group, post vs. before SSRI treatment | Plasma | Human | Down |
| Study M741 | Type4 | remitter group vs. non-remitter group, baseline | Plasma | Human | Up |
| Study M758 | Type1 | CUMS group vs. control group | Ventral tegmental area | Sprague-Dawley rat | Down |
| Study M758 | Type1 | CUMS group vs. control group | Nucleus accumbens | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + high dose of volatile oil group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of Shuganheweitang group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of terpenoid group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M760 | Type1 | CUMS group vs. control group | Hippocampus | Rat | Down |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M767 | Type1 | CUMS group vs. control group | Cortex | C57BL/6 mouse | Down |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Amygdala | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Striatum | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Cortex | C57BL/6 mouse | Up |
| Study M777 | Type1 | HFCS-MFD group vs. control group | Serum | C57Bl/6J mouse | Down |
| Study M810 | Type2 | post-rTMS treatment vs. baseline | Plasma | Human | Down |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M816 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M816 | Type2 | CUMS + middle dose of Baihe Jizihuang Tang group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M816 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Up |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Up |
| Study M822 | Type1 | CUS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M822 | Type1 | CUS group vs. control group | Cortex | Sprague-Dawley rat | Down |
| Study M823 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M823 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M823 | Type2 | CUMS + albiflorin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M832 | Type3 | dehydrozingerone 1h group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M832 | Type3 | escitalopram group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M832 | Type3 | dehydrozingerone 3h group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M835 | Type1 | CRS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M848 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M848 | Type2 | CRS + dexamethasone group vs. CRS group | Serum | C57BL/6 J mouse | Up |
| Study M851 | Type1 | corticosterone group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M851 | Type2 | corticosterone + high dose of Zhi-Zi-Hou-Po Decoction group vs. corticosterone group | Hippocampus | Sprague-Dawley rat | Up |
| Study M851 | Type2 | corticosterone + fluoxetine group vs. corticosterone group | Hippocampus | Sprague-Dawley rat | Up |
| Study M889 | Type1 | CUMS group vs. control group | Hippocampus | BALB/c mouse | Down |
| Study M889 | Type1 | CUMS group vs. control group | Serum | BALB/c mouse | Down |
| Study M889 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + low dose of Jiaotai Pills group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + low dose of Jiaotai Pills group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + high dose of Jiaotai Pills group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + high dose of Jiaotai Pills group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M898 | Type1 | end-stage renal disease with depression group vs. end-stage renal disease without depression group | Serum | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M918 | Type1 | methamphetamine group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M920 | Type1 | anhedonia-susceptible group vs. control grou | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M922 | Type1 | CUMS group vs. control group | Dorsal raphe nucleus | Sprague-Dawley rat | Down |
| Study M922 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M922 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M922 | Type2 | CUMS + middle dose of P. orientalis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + high dose of P. orientalis group vs. CUMS group | Dorsal raphe nucleus | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + high dose of P. orientalis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + middle dose of P. orientalis group vs. CUMS group | Dorsal raphe nucleus | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + high dose of P. orientalis group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + fluoxetine group vs. CUMS group | Dorsal raphe nucleus | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + middle dose of P. orientalis group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M923 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M928 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Amygdala | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Striatum | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Serum | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Amygdala | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Striatum | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M974 | Type2 | CRS + transcranial ultrasound stimulating group vs. CRS group | Dorsal raphe nucleus | C57BL/6 mouse | Up |
| Study M978 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M978 | Type2 | CUMS + low dose of Rehmanniae Radix group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M978 | Type2 | CUMS + fluoxetine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M978 | Type2 | CUMS + high dose of Rehmanniae Radix group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M979 | Type1 | acute myocardial infarction group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M979 | Type2 | acute myocardial infarction + ABR-215757 group vs. acute myocardial infarction group | Hippocampus | Sprague-Dawley rat | Up |
| Study M979 | Type2 | acute myocardial infarction + Shuangxinfang group vs. acute myocardial infarction grou | Hippocampus | Sprague-Dawley rat | Up |
| Study M980 | Type1 | CMS group vs. control group | Olfactory bulb | C57BL/6J mouse | Down |
| Study M983 | Type2 | adolescent MDD group, post-treatment vs. baseline | Plasma | Human | Up |
| Study M985 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M985 | Type1 | CUMS group vs. control group | Colon | C57BL/6J mouse | Down |
| Study M985 | Type2 | CUMS + indole acetic acid group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |
| Study M994 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M994 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M994 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + Uncaria rhynchophylla extract group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + Uncaria rhynchophylla extract group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M996 | Type1 | CUMS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M997 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M997 | Type2 | CUMS + tryptophan supplementation group vs. CUMS group | Serum | C57BL/6 mouse | Up |
| Study M998 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M998 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |